Tachon G, et al. - Using three different public datasets, researchers assessed the clinical significance of the transcription factor Mesenchyme Homeobox 2 (MEOX2) in gliomas. The Cancer Genome Atlas (TCGA), The Chinese Glioma Genome Atlas (CGGA) and the US National Cancer Institute Repository for Molecular Brain Neoplasia Data (Rembrandt) were used to evaluate the expression of MEOX2 according to IDH1/2 molecular profile and patient survival. They also used 112 glioma clinical samples (including 56 IDH1 wildtype glioblastomas, 7 IDH1 wild-type lower grade gliomas, and 49 IDH1 mutated lower grade gliomas) to assess the prognostic significance of MEOX2 protein expression. Possibly for the first time, MEOX2 was identified as one of the transcription factors that had the closest relation to overall survival in glioma. Also, an association between MEOX2 expression and IDH1/2 wildtype molecular subtype, as well as a significant correlation of MEOX2 expression with overall survival of all gliomas and, more interestingly, to lower grade glioma, was observed.